An additional bispecific, humanized IgG1 antibody that's beneath investigation is zenocutuzumab (MCLA-128), which acts by way of two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by using ADCC. MCLA-128 capabilities through a ‘dock and block’ system whereby just one arm in the antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/